CytoSorbents announces EU launch and availability of PuriFi blood pump
Betsy Goodfellow | June 14, 2024 | News story | Medical Communications | CytoSorbents, EU, Haematology, PuriFi, blood pump
CytoSorbents Corporation has announced the launch and immediate availability of its PuriFi haemoperfusion machine in the EU following its approval and certification through the EU Medical Device Regulation (MDR).
The device features various innovations which separate it from existing haemoperfusion pumps, such as a pre-assembled adult and paediatric blood line kit, auto-priming, an auto-levelling bubble catcher, a touchscreen user interface with a user-friendly set-up guide, optional blood warming and a rapid 10-minute set-up time.
It is intended that these innovations will enable an easier and faster way to administer blood purification for critically ill and cardiac surgery patients.
Vincent Capponi, president and chief operating officer at CytoSorbents, commented: “We are excited to launch the PuriFi pump, the result of a two-year development programme with our original equipment manufacturer (OEM) partner, the Medica Group. Innovation is a key growth driver for us and the feature-rich, easy-to-use PuriFi pump exemplifies this. During the past year, we have been diligently preparing for this product launch, including extensive beta testing of the pumps, sales and technical training for both direct sales teams and select distributors, developing new marketing collateral, establishing a hardware and service maintenance programme, prioritising key sales targets and working with Medica to ensure availability of machines and bloodlines under MDR. We are pleased to finally begin commercialisation.”
Betsy Goodfellow
Related Content
Sharp invests $100m in US and EU manufacturing and packaging facilities
Sharp Services, a pharmaceutical packaging and sterile manufacturing specialist, has announced investments totalling $100m across …
Sarclisa recommended for EU approval in newly diagnosed multiple myeloma
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended Sanofi’s …
EU approval granted for rare kidney disease treatment
The EU has granted marketing authorisation (MA) for Filspari – CSL Vifor and Travere Therapeutics’ …
